BioSpace News Archive

Ventus Therapeutics, Inc. announced that the company has entered into an exclusive worldwide license agreement with Novo Nordisk A/S to develop and commercialize candidates from Ventus’ portfolio of peripherally-restricted NLRP3 inhibitors.

Almirall S.A. and Simcere Pharmaceutical Grou announced that they have entered into an exclusive licensing agreement for Simcere’s IL-2 mutant fusion protein autoimmune drug candidate, SIM0278.

BD, a leading global medical technology company, in conjunction with Heart to Heart International, the National Association of Free and Charitable Clinics and Henry Schein Cares, announced that six U.S. free and charitable clinics will be awarded product-based grants worth a total of $360,000 to support point-of-care diagnostic testing in communities with underserved and at-risk patient populations.

PharmaTher Holdings Ltd. today released business highlights and audited financial results for its fiscal year ended May 31, 2022.

AbbVie (NYSE: ABBV) today revealed the spectrum of new data from studies of risankizumab (SKYRIZI®) in Crohn’s disease and upadacitinib (RINVOQ®) in ulcerative colitis and Crohn’s disease that will be presented as live presentations and e-Posters at the United European Gastroenterology (UEG) Week 2022, October 8-11 in Vienna and online.

Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced that it appointed William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors, Jennifer Millian, M.S., M.B.A. as VP of U.S. Operations, and Philip Coxon, Ph.D., as VP of Business Development.

Enanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV Symposium.

ImprimisRx, America’s #1 Ophthalmic Pharmacy™, today announced the availability of Fortisite™, which includes a patent-pending compounded combination of Tobramycin 1.5% and Vancomycin 5%.

Delphinus Medical Technologies, Inc. today announced the closing of a $30 million Series D financing.

Cognition Therapeutics, Inc. announced today that the Company’s president and CEO, Lisa Ricciardi will participate in a panel discussion and host one-on-one meetings at the Cantor Fitzgerald Neurology & Psychiatry Conference taking place in San Francisco from October 6-7, 2022.